Underlying weakness

More to give - keep BUY

Market to improve ahead

If H2 doesn’t step up, '27e won’t stack up

Limited changes post Q1

Consolidated in line weak from JV's

Good Q1e sales, but recent slow-down

Sales miss, solid underlying activity

Estimates down on delayed margin recovery

Jm Ab (Buy, TP: SEK170.00) - Passing the trough

Q1 EBIT was 4% below our estimate and Infront consensus, while EPS fell well short in percentage terms due to a low nominal figure. KPIs did not recover as much as we expected, although JM reiterated its target to increase housing starts to 3,800 units p.a., citing macroeconomic conditions as a key factor. Given the current market outlook, we believe the company has passed the trough on EPS, as we expect starts and sales to recover in late 2025 and 2026. We reiterate our BUY and target price of ...

Margins continue to surprise negatively

Good value

Recovery in the making

Mixed upside potential, despite market recovery expectations

Pent-up demand and falling interest rates remain the backbone for newbuild recovery expectations. However, as the recovery has not yet started, property developers screen as the most attractive long-term, but visibility remains mixed. Diversified construction companies are more attractive on near-term P/Es, although many seem to be fully valued on solid share-price performance over the past six months. We maintain a neutral sector view; NCC and Skanska are our top picks.

Jm Ab (Buy, TP: SEK170.00) - BUY on the dip

JM’s share price has been volatile over the past three years, trading in waves on recovery expectations. As the Swedish residential market has yet to recover, expectations have recently fallen further, and the stock has reached old lows. However, we expect a market recovery in late-2025 and 2026, and we believe this has created an attractive entry point. KPIs (unit sales and unit starts) are our Q1 focus point, as profits are still affected by cycle lows and a trailing profit recognition. We hav...

Selvaag Bolig (Sell, TP: NOK32.00) - Unit sales in line, EPS still tra...

Today’s Q1 trading update showed a unit sales recovery broadly in line with our forecast. However, while starts were above our forecast, our 2025e is unchanged at 700 units. Despite KPIs seemingly recovering as expected, we still see downside risk for the stock given the long lead time to profit and dividends and as the valuation looks high relative to peers. Ahead of the Q1 results (due at 07:00 CET on 21 May), we forecast marginally negative Q1 EPS on few deliveries. We reiterate our SELL and ...

Sales as expected, deliveries above

Bonava (Hold, TP: SEK10.00) - New but recycled targets

Bonava hosted a CMD on 27 March. While focus was on the expected market recovery, it announced ‘new’ financial targets (recycled old ones), in which the EBIT margin and ROE targets refer to new POC accounting starting in 2025, rather than formal IFRS figures. While recovery was the underlying theme, we do not expect it to be reflected in the Q1 results. We reiterate our HOLD and SEK10 target price.

CMD with many positives

Bonava (Hold, TP: SEK10.00) - Another chance to convince

Bonava is due to provide an update on its business plan and strategy at its CMD in Stockholm (27 March). So far, it has not met the financial or operational targets presented at its last CMD, and we note its history of changing its targets; we believe it will be down to results to convince. With our expectation of negative EPS for 2025–2026, and a potential recovery in 2027, we continue to find a better risk/reward elsewhere in the sector. We reiterate our HOLD and SEK10 target price.